Gwendolyn Knowlton Binder S... Net Worth

The estimated Net Worth of Gwendolyn Knowlton Binder S... is at least 612 千$ dollars as of 14 January 2019. Gwendolyn S owns over 1,514 units of Adaptimmune Therapeutics Plc stock worth over 2,686$ and over the last 9 years Gwendolyn sold ADAP stock worth over 609,130$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Gwendolyn S ADAP stock SEC Form 4 insiders trading

Gwendolyn has made over 3 trades of the Adaptimmune Therapeutics Plc stock since 2018, according to the Form 4 filled with the SEC. Most recently Gwendolyn sold 1,514 units of ADAP stock worth 8,130$ on 14 January 2019.

The largest trade Gwendolyn's ever made was selling 25,000 units of Adaptimmune Therapeutics Plc stock on 1 October 2018 worth over 344,750$. On average, Gwendolyn trades about 8,586 units every 23 days since 2016. As of 14 January 2019 Gwendolyn still owns at least 2,487 units of Adaptimmune Therapeutics Plc stock.

You can see the complete history of Gwendolyn S stock trades at the bottom of the page.

What's Gwendolyn S's mailing address?

Gwendolyn's mailing address filed with the SEC is 235 S 21st St, Philadelphia, PA 19103, USA.

Insiders trading at Adaptimmune Therapeutics Plc

Over the last 9 years, insiders at Adaptimmune Therapeutics Plc have traded over 40,532,026$ worth of Adaptimmune Therapeutics Plc stock and bought 384,338,252 units worth 527,131,726$ . The most active insiders traders include Forest Baskett、Scott D Sandell、Anthony A. Jr. Florence. On average, Adaptimmune Therapeutics Plc executives and independent directors trade stock every 20 days with the average trade being worth of 2,827,332$. The most recent stock trade was executed by Cintia Piccina on 18 June 2024, trading 24,531 units of ADAP stock currently worth 22,814$.

What does Adaptimmune Therapeutics Plc do?

adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.

Complete history of Gwendolyn S stock trades at Adaptimmune Therapeutics Plc

Adaptimmune Therapeutics Plc executives and stock owners

Adaptimmune Therapeutics Plc executives and other stock owners filed with the SEC include:

• James Noble,
  Non-Executive Director
• Adrian Rawcliffe,
  Chief Executive Officer, Director
• William Bertrand,
  Chief Operating Officer
• Helen Tayton-Martin,
  Chief Business Officer
• Adrian G. Rawcliffe,
  CEO, Principal Accounting Officer & Director
• Dr. Helen Katrina Tayton-Martin MBA, Ph.D.,
  Co-Founder & Chief Bus. Officer
• William C. Bertrand Jr.,
  Chief Operating Officer
• Gavin Hilary James Wood BA (Hons), ACA,
  Chief Financial Officer
• David Mott,
  Non-Executive Independent Chairman of the Board
• Tal Zvi Zaks,
  Non-Executive Independent Director
• Elliott Sigal,
  Non-Executive Independent Director
• John Furey,
  Non-Executive Independent Director
• Barbara Duncan,
  Non-Executive Independent Director
• Ali Behbahani,
  Non-Executive Independent Director
• Lawrence Alleva,
  Non-Executive Independent Director
• John Lunger,
  Chief Patient Supply Officer
• Elliot Norry,
  Senior Vice President, Chief Medical Officer
• Gavin Wood,
  Chief Financial Officer
• Dr. Arundathy Nirmalini Pandite M.B.A., M.D.,
  Sr. VP of Clinical Devel.
• Dr. Rafael G. Amado,
  Pres of R&D
• Sébastien Desprez,
  VP of Communications & Corp. Affairs
• Margaret Henry,
  Head of PR & Company Sec.
• Dr. Juli P. Miller Ph.D.,
  VP of Investor Relations
• Ravi Viswanathan,
  10% owner
• Scott D Sandell,
  10% owner
• Gwendolyn Knowlton Binder S...,
  EVP, Adaptimmune LLC
• Giles Francis Bertram Kerr,
  Director
• Jonathan Kenneth Charles Kn...,
  Director
• Forest Baskett,
  10% owner
• Ian Michael Laing,
  Director
• Rafael Amado,
  President, R&D
• Peter A. Thompson,
  Director
• Peter W. Sonsini,
  10% owner
• Patrick J Kerins,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• M James Barrett,
  10% owner
• Enterprise Associates 14, L...,
  
• Advisors Llc Orbi Med Capit...,
  
• Peter J Barris,
  10% owner
• Advisors Llc Orbi Med Capit...,
  
• Kristen Hege,
  Director
• Priti Hegde,
  Director
• Andrew R Allen,
  Director
• Cintia Piccina,
  Chief Commercial Officer
• Joanna Elizabeth Brewer,
  Chief Scientific Officer
• Garry E Menzel,
  Director